Canine herpesvirus-1 is a varicellovirus of the sub-family Alphaherpesvirinae with a host range restricted to domestic and wild canids.1 Canine herpes-virus-1 is biologically and molecularly related to several animal and human alphaherpesviruses of ocular importance, including HSV-1, HSV-2, varicella-zoster virus, FHV-1, and BHV-1.2,3 Clinical disease manifestations and severity during primary infection with these viruses, including CHV-1, are age dependent. Fetal and neonatal primary infections with CHV-1 result in severe disseminated disease, characterized by multiorgan hemorrhagic necrosis, and are often fatal.4 Current evidence suggests that primary CHV-1 infections in adult canids are frequently subclinical or cause localized or mild respiratory tract, genital, or mucosal disease.5,6
As is characteristic of the alphaherpesviruses, lifelong latent CHV-1 infection is established in neurons of sensory ganglia and lymphatic tissues during initial exposure in canids surviving primary infection.7,8 Reactivation of these latent infections results in viral shedding and may be subclinical or associated with disease recrudescence, including genital and ocular disease.9–11 Ocular lesions reported with naturally acquired recrudescent CHV-1 disease include dendritic ulcerative keratitis and conjunctivitis.11
Canine herpesvirus-1 has a worldwide distribution and high prevalence of exposure in domestic dog populations.7,12 The clinical features and pathogenesis of primary CHV-1 infection in neonatal dogs have been extensively studied,4,13 but infections of adult dogs have been the subject of few investigations.5,6 The objectives of the study reported here were to determine whether experimental ocular CHV-1 infection is associated with clinical disease in immunologically naïve adult dogs and to characterize the ocular lesions, viral shedding, and serologic response associated with primary CHV-1 ocular infection in dogs.
Materials and Methods
Animals—All protocols were approved by the Animal Care and Use Committee of Cornell University and were conducted in accordance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. Twelve specific pathogen–free (CHV-1–free) Beagles were used, including 8 sexually intact males and 4 sexually intact females. Each dog had negative test results for CHV-1 on 2 consecutive SN assays, bilateral conjunctival swab specimen virus isolations, and bilateral conjunctival swab specimen CHV-1 PCR assays performed at 8-week intervals prior to the study. Dogs were 18 months of age, with body weights ranging from 10.6 to 13.6 kg, at the beginning of the study. Prior to the initiation of the study, results of CBCs, serum biochemical panels, and urinalyses were unremarkable for each dog.
Dogs were randomly assigned to be inoculated with CHV-1 (infection group; n = 8) or virus-free media (control group; 4). All dogs in the infection and control groups were further assigned to 1 of 4 subgroups on the basis of administration of 2 treatments: subconjunctival administration of a corticosteroid 48 hours prior to inoculation and corneal microtrephination at the time of inoculation. Therefore, dogs in the control or infection groups were mock or virally inoculated, respectively, following subconjunctival corticosteroid administration only, corneal microtrephination only, both subconjunctival corticosteroid administration and corneal microtrephination, or no treatment (Figure 1). Regardless of subgroup, dogs in the infection and control groups were housed in separate rooms in noncontiguous facilities. Dogs in the infection group were maintained individually in runs separated by a minimum of 121 cm, and direct contact between dogs was prevented for the duration of the study. Dogs in the control group were maintained together in a single large pen. Strict bioisolation was maintained throughout the study for all personnel in contact with all dogs (ie, hazardous material suits, gloves, boot covers, and foot baths were used). Dogs were acclimated to housing facilities for 4 weeks prior to initiation of the study.
Virus and control inoculation—A CHV-1 field strain isolated from corneal samples of a dog with dendritic ulcerative keratitis treated at the Cornell University College of Veterinary Medicine Hospital for Animals was used for all inoculations. The strain was confirmed to be CHV-1 by use of immunofluorescence, electron microscopy, and gene sequencing as described.11 A stock culture of the CHV-1 isolate was grown in low-passage canine kidney cells in minimum essential medium–Ea with 10% fetal bovine serum,b 5% serum replacement solution,c 2% penicillin-streptomycin solution, 1% amphotericin B solution, and 1% gentamicin sulfate solution. Harvested virus was quantified by use of a standard TCID50 assay in 96-well plates with 8 wells inoculated for each dilution. Titers were calculated by use of the Reed-Muench method on a per-milliliter basis. Final CHV-1 concentration was 106 TCID50/mL. Virus-free medium (minimum essential medium–E with 10% fetal bovine serum, 5% serum replacement solution, 2% penicillin-streptomycin solution, 1% amphotericin B solution, and 1% gentamicin sulfate solution) was prepared identically as for the CHV-1 titration to be used for control group inoculations.
Dogs in the subconjunctival corticosteroid subgroups received 10 mg of methlyprednisolone acetate solutiond subconjunctivally in the right eye only. Injections were performed with a 25-gauge needle following the installation of a single drop of topical ophthalmic anesthetic.e The corticosteroid bleb was placed under the dorsal aspect of the bulbar conjunctiva, adjacent to the conjunctival fornix. After 48 hours, inoculations then were performed in all dogs by use of 0.2 mL of CHV-1 solution (infection group) or 0.2 mL of virus-free medium (control group). Prior to inoculation, each dog was sedated with hydromorphone (0.1 mg/kg), acepromazine (0.1 mg/kg), and glycopyrrolate (0.004 mg/kg) administered IV. Dogs not assigned to microtrephination subgroups were inoculated by use of the ocular drop method,14 which was performed by applying the inoculum directly onto the corneal surface of the right eye only, followed immediately by gentle manual massage of the closed eyelids for 60 seconds. The microtrephination technique was performed as originally described.15 Sterile glass capillary tubesf with an internal diameter of 1.1 mm were loaded by capillary action with the inoculum. Capillary tubes were aligned perpendicular to the corneal surface of the right eye only and then gently pressed against the corneal epithelium with simultaneous rotation of the tube end to produce small rings of slight epithelial damage, while simultaneously flooding the ocular surface with inoculum. A single trephination was made in the axial portion of the cornea and 2 in each of the 8 meridians to create 17 inoculation sites/cornea. Immediately following microtrephination, the eyelids were manually held closed for 60 seconds and gently massaged.
Clinical examination—Complete physical and ophthalmologic examinations, including slit-lamp biomicroscopy,g indirect ophthalmoscopy, Schirmer I tear testing, and corneal application of fluorescein and rose bengal stains, were performed on each dog prior to initiation of the study. Ophthalmologic examination of both eyes via slit-lamp biomicroscopy, before and after application of fluorescein and rose bengal stains, was performed daily for the first 21 days after inoculation, every other day for the following 14 days, and then at PIDs 63, 119, and 224. Corneal stain was thoroughly flushed from the ocular surface with sterile eye wash solution following examination. A modified herpesvirus ocular disease clinical scoring system was used to quantify examination findings. The following ocular variables were scored: blepharospasm (0 = none, 1 = mild, 2 = moderate, and 3 = severe), ocular discharge (0 = none, 1 = mild, 2 = moderate, and 3 = severe), conjunctival hyperemia (0 = none, 1 = mild, 2 = moderate, and 3 = severe), chemosis (0 = none, 1 = mild, 2 = moderate, and 3 = severe), and corneal epithelial ulceration (0 = none, 1 = puncate ulcerations, 2 = 1 or more dendritic ulcerations, and 3 = geographic ulcerations). The minimum total clinical score possible with this system was 0, and the maximum total clinical score possible was 15. Physical examinations were performed every other day during the first 35 days after inoculation and then at PIDs 63, 119, and 224.
Virologic sample collections—Conjunctival swab specimens were collected from both eyes on PIDs 0, 3, 5, 7, 10, 15, 21, 28, 35, 63, 119, and 224 for CHV-1 PCR assay and virus isolation. Following clinical scoring, dry swabsh were vigorously brushed across the dorsal and ventral conjunctival fornices of each eye of all dogs. Separate swabs were used for the right and left eyes. Swabs for virus isolation were immediately placed in sterile tubes containing viral transport medium (ie, Leibovitz L-15 mediumi with 0.25% bovine serum albumin solution, 1% amphotericin B solution, and 1% gentamicin sulfate solution) and processed within 2 hours after collection. Swab specimens for PCR assay were stored in sterile tubes at −80°C for up to 5 days prior to analysis. Serum for CHV-1 SN titers was collected on PIDs 0, 7, 14, 21, 28, 35, 63, 119, and 224. Blood samples were collected into tubes with EDTA anticoagulant on PIDs 0, 3, 7, 14, 21, 28, 35, 63, 119, and 224 for buffy coat extraction and CHV-1 PCR assay. Blood samples were centrifuged for 10 minutes at 6,000 × g, and buffy coat and serum samples were manually extracted, snap frozen in liquid nitrogen, and stored at −80°C until analysis.
Sample preparation and automated nucleic acid extraction—Five hundred microliters of filtered PBS solution was added to the microcentrifuge tube containing each conjunctival swab, then tubes were vortexed for 10 seconds, inverted, and centrifuged at 16,000 × g for 5 minutes. The supernatant and swab were removed, and the cell pellet was used for the nucleic acid extraction. Nucleic acid extraction was performed by use of an automated nucleic acid extraction systemj according to the manufacturer's instructions.
Quantitative real-time PCR assay and viral load determination—All samples were analyzed for the presence of the canine GAPDH gene to determine the efficiency of nucleic acid extraction.16 The real-time PCR assay used for CHV-1 detection was designed by the Lucy Whittier Molecular and Diagnostic Core Facility (Davis, Calif) and targeted part of the glycoprotein B gene (Genbank accession No. AF361073).
Each PCR reaction contained 20X primer and probes for the respective system, with a final concentration of 400nM for each primer and 80nM for the probe and the commercially available PCR mastermixk containing 10mM Tris-HCl (pH, 8.3), 50mM KCl, 5mM MgCl2, 2.5mM deoxynucleoside triphosphates, 0.625 U recombinant thermostable DNA polymerase/reaction, 0.25 U of uracil N-glycosylase/reaction, and 5 μL of the diluted cDNA sample in a final volume of 12 μL. The samples were placed in 384-well plates and amplified in an automated fluorometer.l Standard amplification conditions were used as follows: 2 minutes at 50°C, 10 minutes at 95°C, 40 cycles of 15 seconds at 95°C, and 60 seconds at 60°C. Fluorescent signals were collected during the annealing temperature, and threshold cycle values were determined with a threshold of 0.08 and baseline values of 3 to 16. The viral load (number of viral copies) of samples with positive results was calculated as described.16
CHV-1 SN assay—All serum samples were analyzed concurrently in the same session. Test sample, high-positive control, low-positive control, and negative control sera were heat inactivated in a 56°C water bath for 30 minutes. Test medium (50 μL of minimum essential medium–E with heat-inactivated 10% fetal bovine serum and 2% penicillin-streptomycin solution) was added to plate wells along with 50 μL of test sample, and 2-fold serial dilutions were performed. The working dilution of virus (100 TCID50/50 μL) and back titrations of 10−1, 10−2, and 10−3 dilutions were prepared and added to test wells. Plates were incubated for 1.5 hours at 37°C. Canine skin SV-40 cells were added to the wells and incubated for 3 days in a 37°C humidified 5% CO2 incubator. An inverted microscope was used to examine wells for cytopathic effect, and antibody titers were calculated.
Virus isolation—Isolations were performed with A-72 canine cells and a laboratory-developed canine skin cell line in minimum essential medium–E with 10% fetal bovine serum, 5% serum replacement solution, 2% penicillin-streptomycin solution, 1% amphotericin B solution, and 1% gentamicin sulfate solution. Cultures were incubated at 37°C, checked at 24-hour intervals for cytopathic effect, subcultured every 5 to 7 days, and held for 21 days. Cell cultures with cytopathic effects typical of CHV-1 were stained with anti–CHV-1 polyclonal antiserum conjugated to fluorescein isothiocyanatem to confirm viral identification.
Statistical analysis—To facilitate data analysis and interpretation, ocular clinical disease scores were summarized into 1 dichotomous variable; dogs that received at least 1 score > 0 (ie, dogs with conjunctivitis, keratitis, or both) were coded as 1, and dogs that had all scores equal to 0 (ie, dogs with no evidence of conjunctivitis or keratitis) were coded as 0. This variable was used as the dependent variable for a mixed logistic regression model fitted by use of a software program.n The following variables were used as independent variables: study group, inoculation method, and preinoculation subconjunctival corticosteroid administration. Furthermore, the animal identification number was added to the model as a random effect to control for the repeated-measures nature of the study. A second mixed logistic regression model was also fitted by use of the software program; the dependent variable for this model was ocular viral shedding (detected or not detected by virus isolation), and the same independent variables were used in this model. Descriptive statistics were determined with a software program.o A value of P b 0.05 was considered significant for all comparisons.
Results
No abnormalities were detected during initial physical and ophthalmologic examinations. Schirmer I tear test results were > 15 mm/min in both eyes of all dogs, and corneal retention of fluorescein or rose bengal stains was not observed in any dog. Corneal epithelial defects resulting from microtrephination had healed by PID 1 in all dogs and appeared as faint epithelial opacities that did not retain fluorescein or rose bengal stain. These corneal opacities disappeared over the following 3 to 4 days in all dogs. A transient increase in ocular disease scores of the inoculated eye was detected at PID 2 in all dogs that received microtrephination in the infection and control groups, but scores returned to near baseline values by PID 3 (Figure 2). This initial increase in ocular scores was presumed to have resulted from iatrogenic ocular trauma associated with the corneal microtrephination procedure because similar transient changes in ocular disease scores were not detected in dogs inoculated by use of the ocular drop method or in the noninoculated eye of any dog.
Clinical ocular disease scores then began increasing at PID 4 in both eyes of dogs in the infection group and peaked at PID 7 in the inoculated eyes and PID 10 in the noninoculated eyes. All dogs in the infection group had mild to moderate conjunctivitis during this time, characterized by conjunctival hyperemia, chemosis, and mucoid to mucopurulent ocular discharge (Figure 3). Ocular disease scores then slowly decreased over the following 15 days and returned to initial values by PID 35 in all dogs in the infection group. In general, ocular disease scores were higher and increased more quickly in the inoculated eye versus the noninoculated eye of dogs in the infection group. Dogs in the control group did not develop clinically detectable ocular disease at any time during the study after PID 3 (all clinical ocular disease scores = 0), and only control dogs in the microtrephination group had clinical ocular disease scores > 1 during the first 3 days after inoculation. Corneal retention of fluorescein or rose bengal stain was not detected at any time in any dog, and nonulcerative keratitis was not identified at any time during the study. Clinically detectable systemic illness was not detected at any point during the study in dogs from either study group.
Shedding of CHV-1 from the inoculated eye was detected by use of CHV-1 PCR assay in all dogs in the infection group between PIDs 3 and 10 (Figure 4). Two dogs in the infection group also shed virus from the noninoculated eye during this period as detected via CHV-1 PCR assay (Figure 5). Viral loads peaked at PID 5 in both eyes and returned to less than detection limits by PID 15. Virus was never isolated from samples from the noninoculated eye; however, CHV-1 was isolated from samples collected from the inoculated eye of 7 dogs in the infection group on 1 or more days between PIDs 3 and 7 (Figure 6). Virus was isolated on 3 sampling days from 2 dogs, 2 sampling days from 2 dogs, and 1 sampling day from 3 dogs. Mean ± SD viral load for infection group samples between PIDs 3 and 10 was 1.1 × 106 copies/106 cells ± 2.4 × 106 copies/106 cells for samples corresponding with positive virus isolation assays and 1.2 × 104 copies/106 cells ± 4.0 × 104 copies/106 cells for samples corresponding with negative virus isolation assays. Viral DNA was never detected via PCR assay in the buffy coat samples from any dog in either study group. All dogs in the infection group began developing detectable CHV-1 SN antibody titers by PID 7 (Figure 7). Titers peaked at PID 21 and then began to decrease slowly in all dogs. A CHV-1 SN antibody titer was undetectable in 1 dog from the infection group at PID 119, and titers were undetectable in 4 dogs from the infection group at PID 224.
Ocular CHV-1 shedding was not detected via CHV-1 PCR assay or virus isolation at any sampling point during the study in the control group, and no control dogs developed detectable CHV-1 SN titers. Dogs inoculated with CHV-1 were significantly more likely to develop clinical ocular disease (P < 0.001) and shed virus (P < 0.001) than were dogs in the control group. In the infection group, neither preinoculation corneal microtrephination nor subconjunctival cortico-steroid administration significantly affected clinical ocular disease scores (P = 0.63 and P = 0.81, respectively) or detection of ocular viral shedding (P = 0.30 and P = 0.72, respectively).
Discussion
Results of the present study revealed that experimental primary ocular infection of adult dogs with CHV-1 was associated with self-limiting conjunctivitis and ocular viral shedding, which occurred without clinically detectable keratitis or systemic disease. Experimental conditions of this investigation may have clinical relevance because natural transmission of CHV-1 frequently occurs by direct contact with infectious mucosal secretions and because the ocular surface is a plausible site of viral exposure and portal of entry.13 Despite the ubiquitous presence of latent CHV-1 infections in most canine populations and presumed high primary infection rate among immature dogs,7,12 there is a positive correlation between dog age and CHV-1 seroprevalence in some groups.17,18 This suggests that naturally acquired primary CHV-1 infection is not restricted to immature dogs. Alphaherpesvirus superinfection (ie, exogenous reinfection of a host with acquired immunity to 1 viral strain with a different strain of the same virus) may also induce clinical disease similar to primary infection in humans with HSV.19 This phenomenon, although unproven, may also occur in adult dogs previously infected with CHV-1 if multiple strains exist.
Duration of ocular CHV-1 shedding detected in the present study was similar to experimental primary ocular infection with HSV-1 in rabbits and BHV-1 in cattle and naturally acquired HSV-1 infection of humans.20–22 In contrast, viral shedding following experimental primary ocular FHV-1 infection was detected up to PID 29 in cats that had not received corticosteroids and for > 60 days in cats that had received corticosteroids subconjunctivally prior to infection.23,24 Variability in duration of viral shedding among these alphaherpesviruses and hosts likely results from diversity of innate host resistance, host-adaptive immune response, and virus-specific factors.25 The duration of ocular CHV-1 shedding in the present study was also shorter than that reported in dogs with naturally acquired CHV-1 infection and undergoing recrudescent ulcerative keratitis, in which virus was shed from corneal lesions for 2 to 5 weeks.11 This disparity may reflect differences between primary and reactivated infection, or in host immune status, because the dogs of that previous report had systemic immunomodulating diseases and were receiving topically administered and systemically active immunosuppressive medications.
Unsuccessful virus isolation from eyes with conjunctivitis and discrepancies in prevalence and duration of viral shedding between results of virus isolation and CHV-1 PCR assay in the present study likely reflected a greater sensitivity of the PCR assay used because both methods of viral detection consistently yielded positive results during periods of high viral titers, but only PCR assay results were positive from samples that had low titers. Virus isolation also requires actively replicating virus for detection, so periods of positive PCR assay results and negative isolation assay results may occur when antibody-neutralized virus or viral fragments are present. Rose bengal application may also have shortened the duration of detectable shedding via isolation because this stain has a cumulative negative effect on detection of alphaherpesviruses via isolation methods in vitro and in vivo.26,27 This effect on assay sensitivity results from singlet oxygen production when rose bengal is exposed to light. Singlet oxygen possesses diverse antimicrobial properties, including nonspecific antiviral activity.26 Singlet oxygen's antiviral activity is limited to extracellular viruses, is not therapeutic, and does not alter the course of disease.27
Subconjunctival administration of corticosteroids did not significantly affect clinical disease or viral shedding in the present study. The dose of methylprednisolone administered altered adrenocortical function in dogs of similar or greater body weight for at least 9 days following subconjunctival injection.28 Subconjunctival methylprednisolone administration in dogs also inhibits corneal healing following experimental wounding.29 Corticosteroid administration increases ocular disease severity and duration following primary infection with FHV-1 in cats and some strains of HSV-1 in multiple hosts.23,30 Exacerbation of herpetic ocular disease with corticosteroids may result from alterations in host immune response and wound healing.31 Additionally, corticosteroids may modulate infection because of direct effects on virus-host cell interactions. These effects are independent of host immunity and have been detected for both FHV-1 and HSV.30,32 However, only some strains of HSV-1 are sensitive to the effects of corticosteroids, and this strain-dependent characteristic is determined by the viral genome.33 It remains to be determined whether CHV-1 is a corticosteroid-sensitive virus or strains with different corticosteroid responsiveness exist.
Corneal disease was not identified in dogs of this report following healing of traumatic microtrephination lesions. Alphaherpesvirus-induced ulcerative and nonulcerative keratitis can result from direct virus-associated cytopathic effects or immune-mediated mechanisms.34 Corneal lesions frequently develop following viral reactivation in other host species, but are not considered common during naturally acquired primary infection.20,35 Corticosteroid administration and iatrogenic corneal trauma are experimental methods that increase the frequency of corneal lesions during experimental primary alphaherpesvirus infection, but did not result in keratitis in this study. Unique host characteristics, viral factors, or their interactions may contribute to the apparent resistance of adult domestic dogs to alphaherpesvirus keratitis. This hypothesis is also supported by the only clinical report11 of CHV-1 ulcerative keratitis in adult dogs, in which it was suspected that lesions developed during viral reactivation in immunocompromised animals and not during primary infection.
A study36 was conducted to evaluate experimental CHV-1 conjunctival inoculation in five 6-week-old seronegative Collies. One dog developed clinically detectable conjunctivitis (ie, serous ocular discharge, chemosis, and hyperemia) in the inoculated eye 3 days after infection, and the other 4 dogs remained clinically normal. All dogs were euthanatized between 2 and 7 days after inoculation. Conjunctival epithelial necrosis and subepithelial infiltration of lymphocytes and macrophages were observed histologically in inoculated eyes of 2 dogs. Ocular histologic findings were normal in the other 3 dogs. The lower frequency of ocular disease detected in the previous study36 relative to this report and the absence of conjunctivitis in noninoculated eyes might have resulted from differences between the 2 investigations in CHV-1 strain or dose used for infection, dog ages and breeds, or study design. The previous study was designed to determine histologic lesions, and details were not provided regarding frequency or method of clinical examination. In the present study, mild conjunctivitis was observed in some dogs, particularly in noninoculated eyes. The subtle lesions could be difficult to identify without magnification provided by slit-lamp biomicroscopy. Additionally, the most pronounced lesions observed in the present study developed at a time after infection beyond which observations concluded in the previous study. Therefore, it is plausible that most dogs in the previous study were euthanatized during the viral prepatent period and may have proceeded to develop conjunctivitis if euthanatized later.
Previous research suggests that direct ocular inoculation is not required for development of conjunctivitis during primary CHV-1 infection. During a study5 of primary CHV-1 genital infection, conjunctivitis was observed clinically and ocular viral shedding was detected in approximately 40% of 4- to 6-month-old Beagles following intrapreputial or intravaginal inoculation. Conjunctivitis was observed approximately 9 days after inoculation and resolved over 4 to 5 days. Conjunctival CHV-1 shedding was detected as early as 4 days after inoculation and for up to 20 days. All dogs also developed self-limiting genital mucositis, CHV-1 SN titers, and genital mucosal viral shedding. Conjunctivitis was detected less frequently and later after inoculation and was of shorter duration than direct ocular inoculation in the present study. If ocular lesions in the previous study5 resulted from viral spread within the host to anatomic sites distant to the initial site of infection, this implies that viral portal of entry affects severity and duration of disease and viral shedding, but that direct ocular inoculation is not necessary to develop conjunctivitis. Nonocular sites of host entry may result in ocular disease with other alphaherpesviruses, notably HSV-1, in which oral and nasal primary infection can induce ocular lesions following neuron axonal transport of virus to the eyes.37 In these circumstances, centripetal spread of virus to the brainstem with subsequent centrifugal transport to trigeminal neurons not innervating the inoculation site is proposed.37 An apparent requirement of this interneuronal mechanism of viral spread is anatomic proximity of neurons, and it may not be applicable to more distant sites. An alternative explanation for conjunctivitis in the primary genital CHV-1 infection study5 is exogenous viral transmission from genital inoculation sites directly to the eyes, either among dogs or via autoinoculation in individual dogs. Supporting this mechanism, conjunctivitis was not observed in studies6,36,38,39 of primary CHV-1 infection of domestic dogs between 5 weeks and 6 months of age inoculated via the IP, intranasal, and peroral routes or in adult red foxes inoculated IV and PO.
Hematogenous viral dissemination is an additional potential mechanism for development of herpetic ocular disease following nonocular primary infection. Primary infection with varicella-zoster virus, the prototypical member of the Varicellovirus genus, is associated with a biphasic peripheral blood mononuclear cell viremia.40 Although of unclear importance in non-neonates, viremia has been detected in healthy and immunosuppressed adult humans after HSV-1 and HSV-2 primary infection and reactivation.41,42 In those reports,41,42 virus in the blood was leukocyte-associated and HSV-1 replicated and persisted in human leukocytes in vitro.43 Animal alphaherpesvirus DNA, including that of FHV-1, BHV-1, and equine herpesvirus-1, has also been detected in peripheral blood leukocytes of their respective hosts.44–46 Intracellular hematogenous transport is suspected as the primary mechanism of viral dissemination in neonatal systemic CHV-1 infection, and CHV-1 has been isolated from buffy coats of a small percentage of 5- to 12-week-old dogs following experimental oronasal inoculation.38 Canine herpesvirus-1 DNA has also been detected in lymphocytes extracted from retropharyngeal lymph nodes of mature dogs 2 to 4 months following experimental intranasal, IV, and intravaginal inoculation; however, virus was not identified in buffy coat samples from the dogs.8 In the present study, CHV-1 DNA was not identified on the selected sampling days in buffy coat samples of any dog following primary ocular infection. This suggests that CHV-1 viremia does not occur in peripheral blood leukocytes of immunocompetent adult dogs during primary ocular infection. Alternatively, CHV-1 viremia may occur with viral loads less than detection limits of the methods used, transiently, or at time points not evaluated, or it may not be leukocyte associated.
Current use of animals to mimic human primary ocular HSV infection include HSV-1 infection in unnatural host animal species (eg, rodents, rabbits, and primates) and host-adapted pathogens (eg, FHV-1 in cats).23,47 These techniques typically require experimental host manipulation, such as ocular scarification, to induce infection or are associated with more severe ocular and systemic disease than that detected during naturally acquired human infection. Several characteristics of experimental primary ocular CHV-1 infection in dogs may more closely resemble naturally acquired primary ocular HSV disease in humans. There is no evidence suggesting that ocular trauma is required for establishment of HSV infection in humans.48 Primary ocular HSV infection in adults is most commonly asymptomatic or results in self-limiting conjunctivitis and blepharitis, whereas keratitis is less frequent.20 Experimental primary CHV-1 ocular infection in dogs develops without ocular trauma and induces ocular lesions similar to those of humans with primary HSV infection, making this technique potentially useful for comparative studies. Although most primary ocular alphaherpesvirus infections are clinically mild and self-limiting, it is during initial exposure that latent infection is established. Establishment of latency initiates the cycle of recurrent ocular infections in susceptible hosts, and it is this recrudescent disease that is responsible for most of the ocular morbidity attributed to HSV in humans.35 Accurate representations of primary ocular herpesvirus infection are desirable because prevention of primary infection and establishment of latency are potential and attractive points of therapeutic intervention.49
Conjunctivitis develops frequently in adult dogs, and an etiology is often not clinically identifiable.50 There is a paucity of established viral causes of conjunctivitis in dogs, and CHV-1 should be considered a potential etiology of this condition after other causes are excluded. The clinical importance of primary and reactivated CHV-1 infections in the pathogenesis of ocular diseases of adult dogs has not been determined; however, the high prevalence of this virus within the canine population and established biological behavior of related viruses warrant further study.
Abbreviations
BHV-1 | Bovine herpesvirus-1 |
CHV-1 | Canine herpesvirus-1 |
FHV-1 | Feline herpesvirus-1 |
GADPH | Glyceraldehyde-3-phosphate dehydroge nase |
HSV | Herpes simplex virus |
PID | Postinfection day |
SN | Serum neutralization |
Invitrogen Co, Carlsbad, Calif.
Atlantic Biologicals Corp, Atlanta, Ga.
Nu-serum I, BD Biosciences, Bedford, Mass.
Depo-Medrol, methylprednisolone acetate suspension, 40 mg/mL, Pharmacia, Kalamazoo, Mich.
Proparacaine hydrochloride 0.5% ophthalmic solution, Akorn Inc, Buffalo Grove, Ill.
Micro-hematocrit capillary tubes, VWR Scientific Co, West Chester, Pa.
Kowa SL-14, Kowa Co, Tokyo, Japan.
Sterile polyester-tipped applicator, Puritan Medical Products Co, Guilford, Me.
Invitrogen Co, Carlsbad, Calif.
CAS-1820 X-Tractor Gene, Corbett Life Science, Sydney, NSW, Australia.
TaqMan universal PCR mastermix, Applied Biosystems, Foster City, Calif.
ABI Prism 7900HTA Fast, Applied Biosystems, Foster City, Calif.
Canine herpesvirus direct fluorescent antibody conjugate, VMRD Inc, Pullman, Wash.
Glimmix procedure, SAS Institute Inc, Cary, NC.
Freq, Univariate, and Means procedures, SAS Institute Inc, Cary, NC.
References
- 1.↑
Rémond M, Sheldrick P, Lebreton F, et al. Gene organization in the UL region and inverted repeats of the canine herpesvirus genome. J Gen Virol 1996;77:37–48.
- 2.
Manning A, Buchan A, Skinner GR, et al. The immunological relationship between canine herpesvirus and four other herpesviruses. J Gen Virol 1988;69:1601–1608.
- 3.
Tyack SG, Studdert MJ, Johnson MA. Nucleotide sequence of canine herpesvirus homologues of herpes simplex virus type 1 US2, US3, glycoproteins I and E, US8.5 and US9 genes. DNA Seq 1997;7:365–368.
- 4.↑
Carmichael LE, Squire RA, Krook L. Clinical and pathological features of a fatal viral disease of newborn pups. Am J Vet Res 1965;26:803–814.
- 5.↑
Hill H, Maré CJ. Genital disease in dogs caused by canine herpesvirus. Am J Vet Res 1974;35:669–672.
- 6.
Karpas A, Garcia FG, Calvo F, et al. Experimental production of canine tracheobronchitis (kennel cough) with canine herpesvirus isolated from naturally infected dogs. Am J Vet Res 1968;29:1251–1257.
- 7.
Burr PD, Campbell ME, Nicolson L, et al. Detection of canine herpesvirus 1 in a wide range of tissues using polymerase chain reaction. Vet Microbiol 1996;53:227–237.
- 8.↑
Miyoshi M, Ishii Y, Takiguchi M, et al. Detection of canine herpesvirus DNA in the ganglionic neurons and lymph node lymphocytes of latently infected dogs. J Vet Med Sci 1999;61:375–379.
- 9.
Poste G, King N. Isolation of a herpesvirus from the canine genital tract: association with infertility, abortion and stillbirths. Vet Rec 1971;88:229–233.
- 10.
Okuda Y, Hashimoto A, Yamaguchi T, et al. Repeated canine herpesvirus (CHV) reactivation in dogs by an immunosuppressive drug. Cornell Vet 1993;83:291–302.
- 11.↑
Ledbetter EC, Riis RC, Kern TJ, et al. Corneal ulceration associated with naturally occurring canine herpesvirus-1 infection in two adult dogs. J Am Vet Med Assoc 2006;229:376–384.
- 12.
Reading MJ, Field HJ. A serological study of canine herpesvirus-1 infection in the English dog population. Arch Virol 1998;143:1477–1488.
- 13.↑
Carmichael LE. Herpesvirus canis: aspects of pathogenesis and immune response. J Am Vet Med Assoc 1970;156:1714–1721.
- 14.↑
Gallardo E. Primary herpes simplex keratitis: clinical and experimental study. Arch Ophthalmol 1943;30:217–220.
- 15.↑
Jones BR, Al-Hussaini MK. Therapeutic considerations in ocular vaccinia. Trans Ophthalmol Soc U K 1963;83:613–631.
- 16.↑
Pusterla N, Wilson WD, Conrad PA, et al. Cytokine gene signatures in neural tissue of horses with equine protozoal myeloencephalitis or equine herpes type 1 myeloencephalopathy. Vet Rec 2006;159:341–346.
- 17.
Lacheretz A, Cognard S. Epidemiology and serological diagnosis of canine herpesvirus infection [in French]. Rev Méd Vét 1998;149:853–856.
- 18.
Ronsse V, Verstegen J, Onclin K, et al. Risk factors and reproductive disorders associated with canine herpesvirus-1 (CHV-1). Theriogenology 2004;61:619–636.
- 19.↑
Remeijer L, Maertzodorf J, Buitenwerf J, et al. Corneal herpes simplex virus type 1 superinfection in patients with recrudescent herpetic keratitis. Invest Ophthalmol Vis Sci 2002;43:358–363.
- 20.↑
Darougar S, Wishart MS, Viswalingam ND. Epidemiology and clinical features of primary herpes simplex virus ocular infection. Br J Ophthalmol 1985;69:2–6.
- 21.
Romanowski EG, Bartels SP, Gordon YJ. Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model. Invest Ophthalmol Vis Sci 1999;40:378–384.
- 22.
Schang LM, Jones C. Analysis of bovine herpesvirus 1 transcripts during primary infection of trigeminal ganglia of cattle. J Virol 1997;71:6786–6795.
- 23.
Nasisse MP, Guy JS, Davidson MG, et al. Experimental ocular herpesvirus infection in the cat. Sites of virus replication, clinical features and effects of corticosteroid administration. Invest Ophthalmol Vis Sci 1989;30:1758–1768.
- 24.
Haid C, Kaps S, Gönczi E, et al. Pretreatment with feline interferon omega and the course of subsequent infection with feline herpesvirus in cats. Vet Ophthalmol 2007;10:278–284.
- 25.↑
Brandt CR. The role of viral and host genes in corneal infection with herpes simplex virus type 1. Exp Eye Res 2005;80:607–621.
- 26.↑
Chodosh J, Banks MC, Stroop WC. Rose bengal inhibits herpes simplex virus replication in vero and human corneal epithelial cells in vitro. Invest Ophthalmol Vis Sci 1992;33:2520–2527.
- 27.↑
Brooks SE, Kaza V, Nakamura T, et al. Photoinactivation of herpes simplex virus by rose bengal and fluorescein. In vitro and in vivo study. Cornea 1994;13:43–50.
- 28.↑
Regnier A, Toutain PL, Alvinerie M, et al. Adrenocortical function and plasma biochemical values in dogs after subconjunctival treatment with methylprednisolone acetate. Res Vet Sci 1982;32:306–310.
- 29.↑
Martin CL. Effect of topical vitamin A, antibiotic, mineral oil, and subconjunctival corticosteroid on corneal epithelial wound healing in the dog. J Am Vet Med Assoc 1971;159:1392–1399.
- 30.
Zamansky GB, Lee BP, Chang RK, et al. Quantitation of herpes simplex virus in rabbit corneal epithelium. Invest Ophthalmol Vis Sci 1985;26:873–876.
- 31.↑
Cooper JA Jr, Daniels CA, Trofatter EF Jr. The effect of prednisolone on antibody-dependent cell-mediated cytotoxicity and the growth of type 1 herpes simplex virus in human cells. Invest Ophthalmol Vis Sci 1978;17:381–385.
- 32.
Stiles J, Pogranichniy R. Detection of virulent feline herpesvirus-1 in the corneas of clinically normal cats. J Feline Med Surg 2008;10:154–159.
- 33.↑
Kaufman HE, Varnell ED, Centifanto YM, et al. Effect of herpes simplex virus genome on the response of infection to corticosteroids. Am J Ophthalmol 1985;100:114–118.
- 34.↑
Remeijer L, Osterhaus A, Verjans G. Human herpes simplex virus keratitis: the pathogenesis revisited. Ocul Immunol Inflamm 2004;12:255–285.
- 35.↑
Wishart MS, Darougar S, Viswalingam ND. Recurrent herpes simplex virus ocular infection: epidemiological and clinical features. Br J Ophthalmol 1987;71:669–672.
- 36.↑
Wright NG, Cornwell HJC. The susceptibility of six-week old puppies to canine herpes virus. J Small Anim Pract 1970;10:669–674.
- 37.↑
Tullo AB, Shimeld C, Blyth WA, et al. Spread of virus and distribution of latent infection following ocular herpes simplex in the non-immune and immune mouse. J Gen Virol 1982;63:95–101.
- 38.↑
Appel MJ, Menegus M, Parsonson IM, et al. Pathogenesis of canine herpesvirus in specific-pathogen-free dogs: 5- to 12-week old pups. Am J Vet Res 1969;30:2067–2073.
- 39.
Reubel GH, Pekin J, Venables D, et al. Experimental infection of European red foxes (Vulpes vulpes) with canine herpesvirus. Vet Microbiol 2001;83:217–233.
- 40.↑
Mainka C, Fuss B, Geiger H, et al. Characterization of viremia at different stages of varicella-zoster virus infection. J Med Virol 1998;56:91–98.
- 41.
Naraqi S, Jackson GG, Jonasson OM. Viremia with herpes simplex type 1 in adults. Four nonfatal cases, one with features of chicken pox. Ann Intern Med 1976;85:165–169.
- 42.
Craig CP, Nahmias AJ. Different patterns of neurologic involvement with herpes simplex virus types 1 and 2: isolation of herpes simplex virus type 2 from buffy coat of two adults with meningitis. J Infect Dis 1973;127:365–372.
- 43.↑
Rinaldo CR Jr, Richter BS, Black PH, et al. Persistent infection of human lymphoid and myeloid cell lines with herpes simplex virus. Infect Immun 1979;25:521–525.
- 44.
Chesters PM, Allsop R, Purewal A, et al. Detection of latency-associated transcripts of equid herpesvirus 1 in equine leukocytes but not in trigeminal ganglia. J Virol 1997;71:3437–3443.
- 45.
Mweene AS, Okazaki K, Kida H. Detection of viral genome in non-neural tissues of cattle experimentally infected with bovine herpesvirus 1. Jpn J Vet Res 1996;44:165–174.
- 46.
Westermeyer HD, Thomasy SM, Kado-Fong H, et al. Assessment of viremia associated with experimental primary feline herpesvirus infection or presumed hereptic recrudescence in cats. Am J Vet Res 2009;70:99–104.
- 47.
Falcon MG, Jones BR. Herpes simplex keratitis: animal models to guide the selection and optimal delivery of antiviral chemotherapy. J Antimicrob Chemother 1977;3 (suppl A):83–89.
- 48.↑
Kaye SB, Shimeld C, Grinfeld E, et al. Non-traumatic acquisition of herpes simplex virus infection through the eye. Br J Ophthalmol 1992;76:412–418.
- 49.↑
Richards CM, Shimeld C, Williams NA, et al. Induction of mucosal immunity against herpes simplex virus type 1 in the mouse protects against ocular infection and establishment of latency. J Infect Dis 1998;177:1451–1457.
- 50.↑
Lund EM, Armstrong PJ, Kirk CA, et al. Health status and population characteristics of dogs and cats examined at private veterinary practices in the United States. J Am Vet Med Assoc 1999;214:1336–1341.